Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib + Fulvestrant in advanced ER+/HER2- breast cancer
NCT04650581Phase 3Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jan 2021
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of ipatasertib in breast cancer, sponsored by Canadian Cancer Trials Group. Started Jan 2021; status: active, not recruiting.
02
Drugs
ipatasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04650581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04650581.